Evidence map›Paper›PMID 28713796›Full record

ArticleClinical and translational imaging2017

Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.

Hossein Jadvar

Abstract read
In one paragraph

Article in Clinical and translational imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Hossein JadvarDivision of Nuclear Medicine, Department of Radiology, University of Southern California, Los Angeles, California, USA.
University of Southern California · US

Funding

FDG PET-CT in Metastatic Prostate CancerR01CA111613 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JADVAR, HOSSEIN · 2005 to 2010
$2.5M
Pilot Human Studies of FMAU PET in Prostate CancerR21EB017568 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JADVAR, HOSSEIN · 2015 to 2016
$433k
[F18]FMAU in Prostate CancerR21CA142426 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JADVAR, HOSSEIN · 2009 to 2010
$393k
NCI NIH HHS R01 CA111613NCI NIH HHS R21 CA142426NIBIB NIH HHS R21 EB017568
6 · The paper itself

Abstract

purposeThere is increasing interest in focal therapy (male lumpectomy) of localized low-intermediate risk prostate cancer. Focal therapy is typically associated with low morbidity and provides the possibility of retreatment. Imaging is pivotal in stratification of men with localized prostate cancer for active surveillance, focal therapy or radical intervention. This article provides a concise review of focal therapy and the evolving role of imaging in this clinical setting.

methodsWe performed a narrative and critical literature review by searching PubMed/Medline database from January 1997 to January 2017 for articles in the English language and the use of search keywords "focal therapy", "prostate cancer", and "imaging".

resultsMost imaging studies are based on multiparametric magnetic resonance imaging. Transrectal ultrasound is inadequate independently but multiparametric ultrasound may provide new prospects. Positron emission tomography with radiotracers targeted to various underlying tumor biological features may provide unprecedented new opportunities. Multimodal Imaging appears most useful in localization of intraprostatic dominant index lesions amenable to focal therapy, in early assessment of therapeutic efficacy and potential need for additional focal treatments or transition to whole-gland therapy, and in predicting short-term and long-term outcomes.

conclusionMultimodal imaging is anticipated to play an increasing role in the focal therapy planning and assessment of low-intermediate risk prostate cancer and thereby moving this form of treatment option forward in the clinic.

Indexed as

cancerFocal therapyimagingprostate

Identifiers

PMID28713796
PMCPMC5508749
OpenAlexW2606293298

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.